Close Menu
Five years after it first began developing its mass spec-based prostate cancer diagnostic, Miraculins said this week it is getting ready to begin testing it in order to submit it to the US Food and Drug Administration.
 
Last month, the Winnipeg, Manitoba-based company said a validation study confirmed the ability of its pre-prostate-cancer biomarker diagnostic to weed out 23 percent of unnecessary biopsies and identify 93 percent of patients positive for prostate cancer.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

IBM security researchers warn of a phishing campaign targeted at organizations involved in the distribution of SARS-CoV-2 vaccines, the Verge reports.

The Illinois police have cut the number of DNA tests waiting to be run in about half, CBS Chicago reports.

A researcher accused of smuggling research materials out of the US has pleaded guilty to making false statements, according to the Associated Press.

In Science this week: gene expression signature linked to nonalcoholic fatty liver disease progression, and more.